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Background: Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly
controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial
subjects could facilitate the identification of transcripts that function as prognostic or diagnostic markers of disease
or treatment. The paramount issue for these methods is the ability to produce robust, reproducible, and timely
mRNA expression profiles from peripheral blood. Single-stranded complementary DNA (sscDNA) targets derived
from whole blood exhibit improved detection of transcripts and reduced variance as compared to their
complementary RNA counterparts and therefore provide a better option for interrogation of peripheral blood on
oligonucleotide arrays. High-throughput microarray technologies such as the high-throughput plate array platform
offer several advantages compared with slide- or cartridge-based arrays; however, manufacturer’s protocols do not
support the use of sscDNA targets.
Results: We have developed a highly reproducible, high-through put, whole blood expression profiling
methodology based on sscDNA and used it to analyze human brain reference RNA and universal human reference
RNA samples to identify experimental conditions that most highly correlated with a gold standard quantitative
polymerase chain reaction reference dataset. We then utilized the optimized method to analyze whole blood
samples from healthy clinical trial subjects treated with different versions of interferon (IFN) beta-1a. Analysis of
whole blood samples before and after treatment with intramuscular [IM] IFN beta-1a or polyethylene
glycol-conjugated IFN (PEG-IFN) beta-1a under optimized experimental conditions demonstrated that PEG-IFN
beta-1a induced a more sustained and prolonged pharmacodynamic response than unmodified IM IFN beta-1a.
These results provide validation of the utility of this new methodology and suggest the potential therapeutic
benefit of a sustained pharmacodynamic response to PEG-IFN beta-1a.
Conclusions: This novel microarray methodology is ideally suited for utilization in large clinical studies to identify
expressed transcripts for the elucidation of disease mechanisms of action and as prognostic, diagnostic,
or toxicity markers.* Correspondence: norm.allaire@biogenidec.com
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The study of the blood transcriptome in the context of
clinical pharmacogenomics has generated much interest
in recent years [1,2]. The cellular and molecular compo-
nents of peripheral blood exhibit dynamic responsive-
ness to physiological, environmental, or pathological
stimuli and are in contact with nearly every tissue in the
body, allowing for assessment of systemic responses to
disease or treatment. As such, peripheral blood is a
source of clinically accessible diagnostic, prognostic and
pharmacodynamic (PD) markers [3,4]. This idea is sup-
ported by a growing body of research that describes the
identification of expressed transcripts from human and
animal peripheral blood that can function as indicators
of disease, as prognostic markers of clinical outcome, of
risk of toxicity, and as evidence of a therapy’s pharmaco-
dynamic effects [5-8].
The successful use of gene expression microarrays in
basic research studies has spawned great interest in the
application of this technology to large clinical pharmaco-
genomics and population-based studies [9-11]. However,
microarray cost, the complexity of sample processing and
tracking, and practical limitations in sample throughput
have restricted its utilization in clinical investigations
[12,13]. Microarray manufacturers have responded to
these needs with the recent development of higher-
throughput solutions such as the high-throughput (HT)
plate array or “array of arrays” [14]. This platform was
made possible through reduction and optimization of
probe content and advances in photonics, collectively en-
abling the miniaturization and assembly of 96 arrays into
the spatial arrangement of a conventional microtiter plate.
Our laboratory’s internal validation studies have confirmed
that data from the HT plate array platform is highly con-
cordant to that of industry standard cartridge arrays [15].
RNA is often amplified using T7 RNA polymerase-driven
in vitro transcription (IVT) [16] to produce complementary
RNA (cRNA) targets for hybridization to microarrays.
However, the high concentration of hemoglobin transcripts
in peripheral blood can induce a globin interference effect,
effectively reducing a microarray’s detection sensitivity and
increasing its signal variability [17]. Although effective
methods have been developed to reduce globin interference
[18-20], current methods of mitigation also induce variance
in microarray results [21].
The challenges associated with utilizing cRNA targets
from peripheral blood as probes for microarray investiga-
tions have led to the development of alternative methods
of amplification and the use of single-stranded comple-
mentary DNA (sscDNA) targets from peripheral blood for
microarray hybridization [22,23], effectively improving the
sensitivity of microarray hybridizations for detecting per-
ipheral blood transcripts. Results from our laboratory’s in-
ternal benchmarking experiments analyzing peripheralblood samples have verified that sscDNA targets improve
microarray sensitivity and decrease signal variance as com-
pared with cRNA targets analyzed using globin blocking,
degradation, and depletion methods (data not shown).
In the current study, we have systematically optimized
sscDNA/HT plate array target mass, hybridization para-
meters and washing parameters using 2 highly charac-
terized test RNAs with the goal of developing a HT
methodology for whole blood transcriptional profiling.
Comparative analysis of optimization data against peer-
reviewed expression array [15] and quantitative polymer-
ase chain reaction (qPCR) [24] datasets were used to select
conditions that improved assay reproducibility and sensi-
tivity. The utility of this new array method (BIIB_HT) was
also confirmed through analyses of whole blood samples
from a clinical trial comparing pharmacodynamic changes
following dosing with either interferon (IFN) beta-1a or
polyethylene glycol-conjugated IFN (PEG-IFN) beta-1a.
Results
Relative variable effect
To identify optimal hybridization conditions that both
maximize detection of rare transcripts and minimize
hybridization variance, labeled sscDNAs generated in bulk
from human brain reference RNA (HBRR) and universal
human reference RNA (UHRR) were hybridized to HT-
HGU133A plate arrays using different masses under vary-
ing hybridization and washing conditions. Independent
variables for optimization included target type (cDNA and
cRNA), mass/array titration (1.0-2.5 μg/array), hybridization
cocktail (containing dimethylsulfoxide [DMSO] or tetra-
methylammonium chloride [TMAC]), hybridization strin-
gency (low-stringency hybridization [LSH, 41-43°C] or
high-stringency hybridization [HSH, 48-50°C]), and wash-
ing stringency (low-stringency washing [LSW, 41-43°C] or
high-stringency washing [HSW, 48-50°C]). Hierarchical
analyses were utilized to evaluate the relative impact and
rank of the variables tested and to validate the quality of
the dataset. An initial filter removed all qualifiers that
changed less than 1.5-fold from the median in less than
20% of the data. The remaining 13,898 qualifiers were
then clustered by correlation with complete linkage
(Figure 1A). We also analyzed the dataset using an alter-
native filtering and hierarchical clustering approach. We
repeated calculations and analyses using R and Bioconduc-
tor computational tools as described by Gentleman [25],
and to discover qualifiers that were differentially expressed
between Human Brain Reference RNA (HBRR) and
Universal Human Reference RNA (UHRR) for each condi-
tion tested, we applied the linear modeling approach
(MANOVA) to fit gene expression levels (log2 trans-
formed) according to the defined groups of samples and
Bayesian posterior error analysis as implemented by
Smyth [26]. Qualifiers that exhibited a log-odds score
Figure 1 Comparative analysis of the relative effects of experimental variables on gene expression profiles. A) An initial filter to remove
all qualifiers that changed less than 1.5 fold from the median value in 20% or less of the samples was applied to the dataset. The remaining
13,898 qualifiers were then subjected to hierarchical clustering by correlation with complete linkage. The resultant clustering reflects the
experimental conditions that were used in this study. B) In initial stringent filter was applied to remove all qualifiers that changed less than 2 fold
between human brain reference RNA and universal human reference RNA and a LODS score of >0. The remaining 7128 qualifiers were then
subjected to hierarchical clustering using a Euclidean distance measure with single linkage. The experimental conditions are reflected in the
clustering dendrogram.
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were considered significantly different. This filtering
method reduced the number of qualifiers from 13898 to
7128. The remaining 7128 qualifiers were then clustered
by single linkage using a Euclidean distance measure or
correlation (Figure 1B).
The results from both clustering approaches revealed the
significant effect of the experimental conditions on gene
expression. Using the derived dendrogram, the relative
effects of each condition were ordered from largest to smal-
lest accordingly: sample type > target type > hybridization
buffer > hybridization stringency >wash stringency > target
mass. Interestingly, target type was second only to sample
type in its relative effect on hybridization.
Global quality assessment
Initial scan quality was assessed using 2 metrics: the per-
centage of qualifiers above the background (percent
present), and the scaling factor (SF) that was used to adjust
the median intensity of the array to a predefined target
value. Higher percentages present and lower scaling factors
were well correlated with overall scan quality (Figure 2).
Results showed that DMSO/sscDNA hybridizations gener-
ally resulted in significantly more qualifiers categorized as
present than either cRNA or sscDNA targets in native HT
TMAC hybridizations (p = 4.3 × 10−23 and p = 1.12 × 10−23,
respectively), with the sscDNA target mass positively cor-
related with the percentage present score. Of all DMSO
conditions tested, DMSO_HSH_HSW resulted in thehighest percentage of qualifiers scored as present, although
this percentage was only marginally more than that for
DMSO_HSH_LSW (p = 0.036). Scaling factor scores for
DMSO and TMAC hybridizations were not as well
defined. Scaling factors were lowest for sscDNA targets in
DMSO_HSH_LSW as compared with all other conditions;
however, the lowest scaling factors were produced by
sscDNA targets hybridized and washed under the condi-
tions of TMAC_HSH_HSW. As expected, sscDNA target
mass was found to be negatively correlated with its scaling
factor score.
Normalized, unscaled standard error (NUSE) plots
allow for an assessment of variance within an array and
for determination of the array’s relationship to a group
of arrays [27]. Analysis of cRNA targets hybridized
under native HT conditions resulted in the largest rela-
tive error among all intra-array and inter-array errors
(Figure 3). Conversely, DMSO hybridization resulted in
a lower relative error than any native TMAC conditions,
with the lowest inter-array and intra-array error pro-
duced using sscDNA targets and the hybridization con-
ditions of DMSO_HSH_LSW.
Data analysis to identify optimal assay conditions
The principal component analysis (PCA) method, which
reduces the dimensionality of large data sets and allows
visualization of the overall data structure, was used to
identify experimental HT array hybridization conditions
that produced results that were most highly correlated
Figure 2 Global scan quality. Addition of the cDNA probe in a
DMSO buffer increases detection of expressed transcripts.
Figure 3 Standard error plot. The conditions DMSO HSH_LSW
yielded the smallest variance in assay results and was selected as the
preferred sample processing methodology.
Figure 4 Principal component analysis. The BIIB_HT assay
expression profile was highly correlated with a qPCR “gold standard”.
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identified a total of 164 sscDNA qualifier transcripts that
changed at least 1.5-fold (p = 0.0001) between HBRR and
UHRR samples under one of the experimental condi-
tions and that were also present in the qPCR reference
dataset. These qualifiers showed a clear separation in
clustering between DMSO and TMAC hybridization
cocktails (Figure 4). Furthermore, within each cocktail
cluster, there was a substructure defined by hybridization
and washing stringency that consisted of the all target
masses. The qPCR reference clustered most closely with
the hybridization conditions of DMSO_HSH_LSW
(Figure 4) and these conditions were selected for use
with subsequent analyses.Detection and differential expression of whole-blood
mRNAs encoding IFN beta-1a biological response genes
It has been well established that parenteral administra-
tion of IFN beta induces a robust response in systemic
gene expression [28]. In order to confirm the utility of
this new BIIB_HT method, the optimized assay was uti-
lized for analysis of peripheral blood samples collected
as part of a phase 1 clinical dose- and route-finding
study [29]. In this study, a single intramuscular (IM) in-
jection of unmodified IFN beta-1a 30 μg was adminis-
tered and peripheral blood samples were collected
predose and at 6 hours and 48 hours postdose. Results
showed strong transcript induction at 6 hours (1,398
probe sets, logarithm [base 10] of odds [LOD] score > 0,
±1.5-fold change), with many transcripts returning to
pretreatment levels within 48 hours (110 probe sets,
LOD score > 0, ±1.5-fold change). A list of the transcripts
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ment is presented in Table 1. Transcript analysis showed a
strong induction of several canonical cell signaling path-
ways at 6 hours post treatment, including both previously
reported and novel candidate pharmacodynamic markers
of IFN response. Induced pathways included those involved
in IFN signaling, bacterial and virus pattern recognition
receptors, IFN regulatory factors, cytoplasmic pattern rec-
ognition receptors involved in IFN regulatory factor signal-
ing, and regulation of cytotoxic T lymphocyte-mediated
apoptosis (Additional file 1).
PEGylation modifies the kinetics of IFN beta-1a
transcriptional response in healthy subjects
To further demonstrate the practical utility of this new
methodology, we next compared the peripheral blood tran-
scriptional response with native IM IFN beta-1a versus
PEG-IFN beta-1a in healthy subjects. Healthy volunteers
were administered a single dose of IFN beta-1a (30 μg
given IM) or PEG-IFN beta-1a (63 μg given IM or subcuta-
neously [SC]). For comparison of responses to the 2 drugs,Table 1 Whole blood transcripts most frequently
upregulated by IFN beta-1aa
Gene Symbol Affymetrix ID Fold Change P Valueb LOD Scorec
USP18 219211_at 91.0 1.26E-17 29.6
SIGLEC1 219519_s_at 64.7 2.07E-14 22.3
SPATS2L 222154_s_at 27.2 1.57E-18 31.7
IFI44L 204439_at 26.5 2.54E-14 22.1
HERC5 219863_at 26.2 9.47E-18 29.9
SERPING1 200986_at 23.5 3.28E-12 17.3
RSAD2 213797_at 21.1 6.33E-12 16.7
IFI44 214059_at 20.5 2.70E-13 19.8
OAS3 218400_at 20.3 1.65E-14 22.5
OASL 205660_at 17.7 4.61E-16 26.1
IFIT1 203153_at 15.4 1.59E-13 20.3
RTP4 219684_at 14.6 1.35E-12 18.2
HERC6 219352_at 14.4 1.03E-19 34.4
IFIT3 204747_at 13.8 2.90E-14 22.0
OAS1 205552_s_at 13.3 7.93E-14 21.0
ISG15 205483_s_at 13.1 1.75E-14 22.5
MX1 202086_at 12.2 2.12E-13 20.0
DDX60 218986_s_at 11.4 9.23E-14 20.8
OAS2 204972_at 9.7 1.36E-11 15.9
LY6E 202145_at 7.0 1.80E-11 15.6
aResults are from whole blood samples collected from healthy volunteers
6 hours post-dose with 30 μg IM IFN beta-1a. A composite IFN beta induction
score was calculated from the geometric mean of the LOD score intensities of
the top 20 transcripts.
bValues were calculated using F-tests within the software package BRB Array
Tools.
cLOD score, logarithm (base 10) of odds score.composite IFN beta induction scores were calculated from
the geometric mean of the normalized intensities of the
top 20 induced transcripts at 6 hours post-dose (Table 1).
Results showed significant differences between IFN beta-1a
and PEG-IFN beta-1a in their induction scores at 6 and
48 hours post-dose (Figure 5), indicating that the up-
regulation of IFN-responsive transcripts was longer follow-
ing dosing with PEG-IFN beta-1a than with IFN beta-1a.
Discussion
Peripheral blood transcriptional expression profiling is
an attractive technology for large pharmacogenomics
studies. However, there have been technical limitations
to generating robust transcriptional profiles from this
important tissue. Although microarray technologies have
been standardized and miniaturized to allow much lar-
ger numbers of samples to be processed in parallel than
was previously possible from tissues and cell lines, there
are few robust methods to utilize these highly parallel
profiling technologies for the analysis of large numbers
of peripheral blood samples. Therefore, development of
new methodologies that enable the reproducible gener-
ation of expression profiles from thousands of patient
blood samples are of paramount importance to transla-
tional research.
We report the development and validation of a highly
sensitive and reproducible HT whole blood expression pro-
filing methodology, designated BIIB_HT. This methodologyFigure 5 Differential kinetics of IFN-responsive gene induction
by IFN beta-1a and PEG-IFN beta-1a. Whole blood samples from
healthy volunteers were analyzed for expression of established
IFN-responsive genes. IFN beta induction scores were calculated as
described in the Methods section.
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tify expressed transcripts that may be useful for elucidating
drug or disease mechanisms of action, or that can function
as prognostic, diagnostic, or toxicity markers. This method
was applied to the analysis of whole blood samples col-
lected from healthy clinical trial subjects before and after
treatment with a single dose of either IM IFN beta-1a or
SC or IM PEG-IFN beta-1a. Study results demonstrate that
PEG-IFN beta-1a induces a more sustained and prolonged
pharmacodynamic response than unmodified IFN beta-1a.
These results provide validation of the utility of this new
methodology and support potential therapeutic benefits of
PEG-IFN beta-1a.
The BIIB_HT method is unique in that it has been opti-
mized specifically to provide the most robust detection of
transcripts from 96 peripheral blood samples in parallel. It
can be used to analyze peripheral blood samples from large
clinical studies in order to identify expressed transcripts
that may be useful for elucidating disease and therapeutic
mechanisms of action, as well as for the identification and
validation of prognostic, diagnostic, or toxicity markers.
BIIB_HT generates sscDNA targets using OvationW
(NuGEN Technologies, San Carlos, CA) amplification
technology and has been optimized to provide the max-
imum sensitivity and specificity when used in combination
with the HTA plate array platform from Affymetrix (Santa
Clara, CA). sscDNA targets were selected as the amplifica-
tion moiety for the development of blood profiling meth-
odologies based on internal benchmarking experiments
(data not shown) and published reports [21,22]. Because
there are currently no reports describing the validation of
sscDNA targets for use with the HTA array platform, a sys-
tematic optimization was required. Specifically, hybridization
and washing conditions and mass/array parameters were
optimized using 2 RNA samples from the MicroArray
Quality Control (MAQC) project to identify conditions
yielding maximum detection and lowest variance sscDNA
targets [24]. The current results were referenced against
native HTA plate array conditions as well as independent
qPCR published results.
TMAC is the native HTA plate array hybridization buf-
fer used with cRNA probes. It has been shown to stabilize
adenine-thymine (AT) base pairs (bp) and minimize the
effect of base composition on oligonucleotide hybridiza-
tions of up to 200 bp. The TMAC hybridization buffer ef-
fectively equalizes the melting points of different probes
therefore allowing probes with different nucleotide com-
positions to be hybridized under identical conditions
[30,31]. On the other hand, sscDNA hybridizations on
glass slide or cartridge arrays typically utilize a 10%
DMSO-based buffer. In the presence of DMSO, denatured
DNA has been shown to renature with homologous DNA
and is not retained by the substrate, thereby reducing the
occurrence of background signals [32]. In the current study,the assay results for TMAC-based versus DMSO-based
hybridizations were markedly different. Hybridization chem-
istry (DMSO or TMAC buffer) influenced hybridization
quality, as indicated by its ranking as the third most im-
portant factor impacting assay results after target type and
sample type (Figure 1). In general, use of TMAC-based
hybridizations with sscDNA probes produced lower num-
bers of detectable transcripts and higher background sig-
nals across the various masses tested (Figure 2). Given
these data, the DMSO-based hybridization buffer was su-
perior to the TMAC-based buffer when sscDNA targets
were used in conjunction with the HTA platform.
When assessing possible errors induced as a function
of experimental variables, NUSE plots are useful for
graphical assessment of array quality. With this method,
standard error estimates for each probe set are normal-
ized to a median value of 1 across all arrays. Box plot
representation of NUSE values are then drawn for each
array and comparative analysis can be conducted for the
entire dataset. Arrays or sets of arrays with a larger
spread are determined to be of higher variance and are
therefore of lower quality. Based on the NUSE plots, use
of DMSO buffer with HSH and LSW conditions gener-
ated the most reproducible data (Figure 3). Interestingly,
mass type and sample type did not strongly influence
assay results. These observations may stem from a mask-
ing effect due to averaging across sample types. Never-
theless, DMSO was clearly superior to TMAC for use
with sscDNA targets on an HT array.
Finally, a PCA in fold change space was used to assess
correlations between the variable conditions tested and a
“gold standard” qPCR reference dataset. In an effort to
normalize all comparisons, qualifiers were selected that
were present in the qPCR reference set, changed at least
1.5-fold between HBRR and UHRR datasets, and had a
p-value of ≤ 0.0001 in any of the conditions tested. This
strategy would allow for penalization of any assay condi-
tions generating a false call as well as for benefiting con-
ditions resulting in a correct call. Results showed a clear
difference between DMSO and TMAC, with each buffer
condition isolated to distinct clusters. Interestingly, the
use of DMSO with LSH, HSW, and 2 μg of sscDNA pro-
duced results that clustered most closely with the qPCR
reference set (Figure 4). Additionally, these optimized
conditions markedly outperformed the standard cRNA/
HT array hybridization conditions (black data point),
suggesting that the methods reported here represent a
significant improvement over the current technology. As
with the other analyses that were performed, of all the
variables tested, the mass of sscDNA for each array had
the smallest effect.
Following optimization of the BIIB_HT technical para-
meters, we sought to apply this new methodology to the
analysis of peripheral blood that was collected as part of
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PEG-IFN beta-1a to healthy subjects. Human IFN beta-1a
is a first-line therapy for patients with relapsing forms of
multiple sclerosis (MS). In multiple clinical trials and
long-term observational studies, IFN beta-1a has been
shown to reduce the development of MS-associated brain
magnetic resonance imaging (MRI) lesions, reduce clinical
relapse rates, and slow the advancement of physical dis-
ability [33-35]. PEG-IFN beta-1a is being developed with
the aim of providing a treatment option that is at least as
safe and effective as current first-line therapies, but with
the added benefits of less frequent dosing and improved
convenience. IFN beta-1a was PEGylated by the attach-
ment of a 20 kDa methoxy-PEG-O-2-methylpropionalde-
hyde to the α-amino group of the N-terminus of IFN
beta-1a, a site that is not critical for binding to the type 1
IFN receptor [36,37].
Previous pharmacokinetic studies have shown that after
a single parenteral injection, PEG-IFN beta1-a was detect-
able in peripheral blood after 7 days as compared with
2 days with unmodified IFN beta-1a [29]. This increased
drug exposure was accompanied by enhanced and sus-
tained expression of the pharmacodynamic IFN biomar-
kers 20,50-oligoadenylate synthetase and neopterin. We
sought to verify if the transcriptional response would re-
flect previous observations of a sustained and prolonged
pharmacodynamic response to PEG-IFN beta-1a as com-
pared with IFN beta-1a using BIIB_HT assay.
We observed a peak median induction score of 11 at
6 hours post IFN beta1-a dosing. A p-value of 0.007 was
calculated by comparison of the IFN induction scores of
the 2 groups at 6 hours post dose (Student’s t test). As
expected, at 48 hours post-dose the induction score of sub-
jects treated with IFN beta1-1a had declined to 10 while
the subjects that received PEG-IFN beta-1a reached a peak
Interferon induction score of 11. Again, the p-value that
was calculated between the induction scores of the 2
groups was statistically significant (p = 0.00001). These
transcriptional data reflect the previously reported transla-
tional sustained pharmacodynamic response observed with
PEG-IFN beta-1a.
Conclusions
The application of HT microarray technologies to large
clinical pharmacogenomics studies represents a unique
opportunity to discover prognostic and predictive markers
of efficacy and safety on a genome scale. These studies
allow a greater understanding of the variable expression of
the human transcriptome in response to therapy in a
highly controlled setting. A barrier to the execution of
these studies is the ability to produce mRNA expression
profiles from peripheral blood in a reproducible and
robust manner. We believe that the methods presented in
this report support the use of HT genome scale expressionanalysis for biomarker discovery from whole blood sam-
ples derived from large clinical trials.
Methods
Experimental design
To eliminate confounding factors associated with labeling
variances, sscDNA targets were generated in bulk from the
highly characterized control RNAs HBRR and UHRR.
Following labeling, sscDNAs were hybridized to HT-
HGU133A plate arrays using different masses under vary-
ing hybridization and washing conditions. These data were
used for comparative analyses between the different
hybridization conditions as well as against historical
HBRR/UHRR cRNA HT array “Genomics” data and 1000
gene “MAQC” qPCR reference data sets to identify optimal
hybridization conditions that both maximize detection of
rare transcripts and minimize hybridization variance.
HBRR and UHRR sscDNA target masses were titrated
from 1.0-2.5 μg/array in DMSO or native TMAC
hybridization buffer. Hybridization Stringency was con-
trolled using temperature. High Stringency Hybridizations
(HSH) or Low Stringency Hybridizations were conducted
at 48-50°C or 41-43°C respectively. Washing stringency was
controlled by adjusting the temperature of the stringent
wash “B” buffer. High Stringency Washes (HSW) were con-
ducted at 48–50°C and Low Stringency Washes were per-
formed at 41–43°C. Experimental conditions for sscDNA
targets were annotated as follows: “Hybridization Cock-
tail”_“Hybridization Stringency”_“Washing Stringency”.
The following conditions were tested for ssDNA targets,
DMSO_HSH_LSW, DMSO_HSH_HSW, DMSO_LSH_H-
SW, TMAC_HSH_LSW, and TMAC_HSH_HSW. All ex-
perimental arrays were processed on a GCAS automated
workstation using the HYB_01 and WASH_01 protocols
(Affymetrix, Santa Clara, CA). Additionally, the results of
experimental sscDNA hybridizations were compared with
previously published data from both cRNA/HT arrays pro-
cessed under standard conditions (IVT_Std) and MAQC
qPCR reference data sets [24]. All experimental conditions
were replicated in triplicate for a total of 120 HTarrays.
Target preparation and labeling of test RNAs
Reference RNAs
Two reference RNAs were used in this study. The Universal
Human Reference RNA (catalog number 740000) and
Human Brain Reference RNA (catalog number AM6050)
samples were purchased from Stratagene/Agilent, Santa
Clara, CA and Ambion/Life Technologies, Grand Island,
NY respectively.
sscDNA target production
sscDNA targets were generated in bulk from 96 replicate
20 ng HBRR or UHRR RNA reactions using the Ovation
RNA automated amplification system V2 (catalog number
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number 4200) NuGEN Technologies, San Carlos, CA,
according to the manufacturer’s recommendations and
then pooled to eliminate any potential confounding factors
associated with labeling variance. sscDNA targets were
mass titrated and then fragmented using FL Ovation
cDNA biotin module (catalog number 4200-A01) NuGEN
Technologies, San Carlos, CA according to the manufac-
ture’s recommendation. Finally, fragmented and bioti-
nylated sscDNAs were re-suspended in either TMAC
hybridization buffer (100 mM MES. 2.5 M TMAC, 20 mM
EDTA, 0.01% Tween-20) or DMSO hybridization buffer
(100 mM MES. 1 M [Na+], 20 mM EDTA, 0.01% Tween-
20) containing the hybridization controls BioB, BioC, BioD,
and cre (P/N 900458, Affymetrix) for HT plates.
cRNA target production
The Affymetrix automated Target Preparation protocol
(TP_0001) was used to prepare 48 replicates of labeled and
unfragmented cRNA in bulk starting from 1 ug of either
UHRR or HBRR according to the GeneChip Expression
Analysis Technical Manual for Cartridge Arrays using the
GeneChip Array Station (catalog number 702064), Affyme-
trix, Santa Clara, CA. Labeled, unfragmented cRNA yields
were calculated for each set of 48 wells and high-quality rep-
licates were then pooled and redistributed to a 96-well plate
for manual fragmentation (data not shown). Fragmented
cRNA test samples were repooled to achieve uniformity
and then split into two aliquots and added to a TMAC
hybridization buffer containing the hybridization controls
BioB, BioC, BioD, and cre (P/N 900458, Affymetrix) for
HT plates.
Target preparation and labeling of test RNAs
sscDNA targets were generated in bulk from 96 replicate
20 ng HBRR or UHRR RNA reactions using the Ovation
RNA automated amplification kit (NuGEN Technologies,
San Carlos, CA), and then pooled to eliminate any poten-
tial confounding factors associated with labeling variance.
sscDNA targets were mass titrated and then fragmented
using FL Ovation cDNA biotin module for automation
(catalog number 4200-A01). Finally, fragmented and bioti-
nylated sscDNAs were resuspended in either TMAC or
DMSO hybridization buffer.
HT hybridization, washing, scanning, and image
processing
sscDNA targets were hybridized to HT plate arrays over-
night and then washed and stained as described above.
Array images (.dat files) were generated using a GeneChip
HT array plate scanner (Affymetrix). Mini “.dat” files were
stitched together using the software HT Image Reader,
v1.0.27 (Affymetrix). Signal values in “.cel” and “.chp” files
and present/absent calls and “.rpt” files containing globalarray quality metrics were generated for each scanned
image using the GCOS Software Statistical Algorithm, v1.0
(Affymetrix). Global quality metrics were imported into
Spotfire (Spotfire Inc., Palo Alto, CA) for visualization.Clinical study design
Nine subjects (3 females and 6 males) from a phase 1, sin-
gle-dose, healthy-volunteer, dose and route finding study
conducted as part of the clinical development of PEG-IFN
beta-1a received a single IM 30-μg injection (6 MIU) of
either IFN beta-1a (AvonexW) or PEG-IFN beta-1a 63-μg
injection (6 MIU). Peripheral blood samples used for ex-
pression profiling were collected prior to injection and at 6
and 48 hours postinjection using the PAXgene Blood RNA
System (Qiagen, Hilden, Germany). This study was per-
formed according to the principles outlined in the Declar-
ation of Helsinki and after approval by the Biogen Idec
Institutional Review Board.Subject information and consent
Prior to any testing under this protocol, including
screening tests and assessments, written informed con-
sent with the approved Informed Consent Form (IFC)
was obtained from the subject in accordance with local
practice and regulations. Written informed consent was
obtained from all subjects participating in this clinical
study conducted by Biogen Idec.
A copy of the ICF, signed and dated by the subject, was
given to the subject. Confirmation of a subject’s informed
consent has been documented in the subject’s medical rec-
ord prior to any testing under this protocol, including
screening tests and assessments.HT whole blood gene expression profiling
RNA extraction from PAXgene-collected blood samples
was conducted using the RNAdvance Blood 96 Well Plate
Protocol (Agencourt, Beverly, MA) on an ArrayPlex liquid
handling system (Beckman Coulter, Brea, CA). RNA con-
centration was determined using a Nano-Drop spectropho-
tometer (Nano-Drop Technologies, Wilmington, NC).
sscDNA targets were generated from 20 ng total RNA
using the Ovation RNA Automated Amplification Kit
(NuGEN Technologies, San Carlos, CA). sscDNA targets
(1–2.5 ug) were fragmented using FL Ovation cDNA Bio-
tin Module for Automation (NuGEN Technologies). Frag-
mented and biotinylated sscDNAs were then resuspended
in DMSO hybridization buffer. Blood sscDNA targets were
hybridized and washed using the newly optimized experi-
mental conditions. HT plate arrays were hybridized under
high stringency conditions (48°C) overnight (16 hours) and
washed under low stringency (41°C) conditions. Array
images were generated and processed as described above.
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All analyses were performed in the R statistical language
using BRB ArrayTools v3.6.3 developed by Dr. Richard
Simon and Amy Peng Lam. Array quartile normalization
and probe set summarizations were performed using the
GCRMA procedure as implemented in BRB Array tools.
Microsoft excel was employed for calculating standard
deviations and coefficients of variation. PCA and hierarch-
ical clustering analysis were performed using Spotfire
(http:/www.spotfire.com) and R software packages.
Additional file
Additional file 1: Top induced pathways 6 post Interferon beta
administration.
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